Toxic Peptide from Wasp Venom Targets Cancer Cell Membrane Phospholipids
|
By LabMedica International staff writers Posted on 15 Sep 2015 |

Image: The Brazilian social wasp Polybia paulista is the source of the Polybia-MP1 anticancer peptide (Photo courtesy of Dr. Mario Palma, Sao Paulo State University).
A toxic peptide component of the venom produced by a South American wasp effectively destroys some types of cancer cells through interactions with groups of phospholipids that are distributed abnormally on their cell membranes.
The Brazilian wasp Polybia paulista produces the bioactive host-defense peptide Polybia-MP1 (MP1) that has known anticancer properties. Its ability to poke holes in cancer cell membranes has been attributed to excess phosphatidylserine (PS) and phosphatidylethanolamine (PE) on the outer membrane of cancer cells. Normal cells, which do not have PS or PE exposed on the cell surface, are not damaged by exposure to MP1.
Investigators at the University of Leeds (United Kingdom) and their collaborators at Sao Paulo State University (Brazil) studied the mode of action of MP1 by creating a series of model membranes with PE and PS distributed in a various patterns internally and externally. They used a combination of membrane permeability assays and imaging techniques in this endeavor.
Results published in the September 1, 2015, issue of Biophysical Journal revealed that PS lipids significantly enhanced the bound concentration of MP1 peptide on the membrane by a factor of seven to eight. Furthermore, a combination of membrane permeability assays and imaging techniques showed that PE significantly increased the susceptibility of the membrane to disruption by MP1 and caused an order-of-magnitude increase in membrane permeability by facilitating the formation of larger transmembrane pores.
Atomic-force microscopy imaging revealed differences in the pore formation mechanism with and without the presence of PE. With PE present, MP1 was more effective at disrupting the membrane, increasing the size of holes that it caused by a factor of 20 to 30. Therefore, PS and PE lipids synergistically combined to enhance the formation of membrane pores by MP1, implying that the combined enrichment of both these lipids in the outer membranes of cancer cells was highly significant for MP1’s anticancer action.
"Formed in only seconds, these large pores are big enough to allow critical molecules such as RNA and proteins to easily escape cells," said contributing author Dr. Joao Ruggiero Neto, professor of biophysics at Sao Paulo State University. "The dramatic enhancement of the permeabilization induced by the peptide in the presence of PE and the dimensions of the pores in these membranes was surprising."
"Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," said senior author Dr. Paul Beales, senior research fellow in structural molecular biology at the University of Leeds. "As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."
Related Links:
University of Leeds
Sao Paulo State University
The Brazilian wasp Polybia paulista produces the bioactive host-defense peptide Polybia-MP1 (MP1) that has known anticancer properties. Its ability to poke holes in cancer cell membranes has been attributed to excess phosphatidylserine (PS) and phosphatidylethanolamine (PE) on the outer membrane of cancer cells. Normal cells, which do not have PS or PE exposed on the cell surface, are not damaged by exposure to MP1.
Investigators at the University of Leeds (United Kingdom) and their collaborators at Sao Paulo State University (Brazil) studied the mode of action of MP1 by creating a series of model membranes with PE and PS distributed in a various patterns internally and externally. They used a combination of membrane permeability assays and imaging techniques in this endeavor.
Results published in the September 1, 2015, issue of Biophysical Journal revealed that PS lipids significantly enhanced the bound concentration of MP1 peptide on the membrane by a factor of seven to eight. Furthermore, a combination of membrane permeability assays and imaging techniques showed that PE significantly increased the susceptibility of the membrane to disruption by MP1 and caused an order-of-magnitude increase in membrane permeability by facilitating the formation of larger transmembrane pores.
Atomic-force microscopy imaging revealed differences in the pore formation mechanism with and without the presence of PE. With PE present, MP1 was more effective at disrupting the membrane, increasing the size of holes that it caused by a factor of 20 to 30. Therefore, PS and PE lipids synergistically combined to enhance the formation of membrane pores by MP1, implying that the combined enrichment of both these lipids in the outer membranes of cancer cells was highly significant for MP1’s anticancer action.
"Formed in only seconds, these large pores are big enough to allow critical molecules such as RNA and proteins to easily escape cells," said contributing author Dr. Joao Ruggiero Neto, professor of biophysics at Sao Paulo State University. "The dramatic enhancement of the permeabilization induced by the peptide in the presence of PE and the dimensions of the pores in these membranes was surprising."
"Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," said senior author Dr. Paul Beales, senior research fellow in structural molecular biology at the University of Leeds. "As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."
Related Links:
University of Leeds
Sao Paulo State University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







